Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders

This article was originally published here

Pharmacy (Basel). 2022 May 15;15(5):607. doi: 10.3390/ph15050607.

ABSTRACT

Peripheral nerve disorders are caused by a range of different etiologies. The range of causes includes metabolic conditions such as diabetes, obesity, and chronic kidney disease. Diabetic neuropathy can be associated with severe weakness and loss of sensation, leading to gangrene and amputation in advanced cases. Recent studies have indicated a high prevalence of neuropathy in patients with chronic kidney disease, also known as uremic neuropathy. Immune-mediated neuropathies, including Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuritis, can lead to significant physical disability. As survival rates continue to improve in cancer, the prevalence of treatment complications, such as chemotherapy-induced peripheral neuropathy, has also increased in treated patients and survivors. Notably, the peripheral neuropathy associated with these conditions can be chronic and long-lasting, significantly affecting the quality of life of those affected and resulting in a heavy socioeconomic burden. This review article explores some of the major emerging clinical and experimental therapeutic agents that have been studied for the treatment of peripheral neuropathy due to metabolic, toxic, and immune etiologies.

PMID:35631433 | DOI: 10.3390/ph15050607

About Antoine L. Cassell

Check Also

Notley says outside firm will review NDP treatment of staff and volunteers

Breadcrumb Links Policy New National Author of the article: The Canadian Press Dean Bennett Publication …